Kadcyla 100mg Injection

Kadcyla 100mg Injection contains the active ingredient Ado-Trastuzumab emtansine. It is a prescription drug utilized for treating HER2-positive breast cancer that has metastasized or has not responded to previous therapies. This medication is a combination of two components: trastuzumab, an antibody that specifically targets HER2 receptors, and emtansine, a chemotherapy agent that destroys cancer cells. It is indicated for the treatment of breast cancer in both early and advanced stages, particularly for patients who experience recurrence within six months following chemotherapy. This drug is effective against tumors that produce an excess of a specific protein known as HER2 protein.

Patients who have residual breast cancer after undergoing chemotherapy and HER2-targeted therapy tend to have a worse prognosis compared to those without residual cancer. It is crucial to inform your physician immediately if you notice side effects such as allergic reactions or unusual bleeding. This medication does not adversely affect the kidneys. In rare instances, infusion reactions may occur. Like many other medications, it can cause mild side effects including nausea, vomiting, diarrhea, and hair loss.